These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6442580)

  • 1. On the pharmacology of the ergot alkaloid elymoclavine.
    Petkov V; Georgiev V; Roussinov K; Grigorov I; Slokoska L; Angelova M; Lazarova M; Getova D; Todorov S; Radomirov R
    Biomed Biochim Acta; 1984; 43(11):1305-16. PubMed ID: 6442580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On some central effects of elymoclavine.
    Roussinov K; Georgiev V; Petkov V; Lazarova M; Petkova B; Shopova S; Markovska V; Getova D; Draganova S
    Acta Physiol Pharmacol Bulg; 1984; 10(4):28-35. PubMed ID: 6442955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of elymoclavine on open field behaviour of rats and pharmacological analysis of its catecholaminergic mechanisms.
    Georgiev V; Getova D
    Methods Find Exp Clin Pharmacol; 1983 Jun; 5(5):281-5. PubMed ID: 6312220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the ergot alkaloid elymoclavine on the level and turnover of biogenic monoamines in the rat brain.
    Petkov VD; Konstantinova E
    Arch Int Pharmacodyn Ther; 1986 May; 281(1):22-34. PubMed ID: 2428322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GABAergic influence on the effects of elymoclavine on exploratory behaviour of rats in open field.
    Georgiev V; Getova D; Petkov V
    Methods Find Exp Clin Pharmacol; 1984 Aug; 6(8):423-7. PubMed ID: 6092797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of transmitter mechanisms in the behavioural effects of angiotensin II.
    Georgiev V
    Pol J Pharmacol Pharm; 1990; 42(6):553-62. PubMed ID: 1983291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of AT II on the exploratory behaviour of rats. Interactions with elymoclavine and bromocryptine.
    Petkova B; Georgiev V; Kambourova T
    Acta Physiol Pharmacol Bulg; 1991; 17(2-3):84-90. PubMed ID: 1819920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some central effects of angiotensin II. Interactions with dopaminergic transmission.
    Georgiev V; György L; Getova D; Markovska V
    Acta Physiol Pharmacol Bulg; 1985; 11(4):19-26. PubMed ID: 3012944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
    Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
    Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cycloalkanecarboxylic esters derived from lysergol, dihydrolysergol-I, and elymoclavine as partial agonists and antagonists at rat 5-HT2A receptors: pharmacological evidence that the indolo[4,3-fg]quinoline system of the ergolines is responsible for high 5-HT2A receptor affinity.
    Pertz HH; Milhahn H; Eich E
    J Med Chem; 1999 Feb; 42(4):659-68. PubMed ID: 10052973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonyliminoimidazolidines, a new class of oral hypoglycemic agents. 4. Toxicity and general pharmacology of 1-[p-[2-(crotonylamino)-ethyl]-phenylsulfonyl]-3-cyclohexy l-2-imino- imidazolidine (CGP 11 112).
    Märki F; Büch O; Delini-Stula A; Kraetz J; Petermann H; Radeke E; Schweizer A; Thomann P; Truog A
    Arzneimittelforschung; 1984; 34(3):247-52. PubMed ID: 6539603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic influence on the effects of angiotensin II in behavioural reactions.
    Georgiev V; György L; Yonkov D; Getova D; Markovska V; Petkova B
    Physiol Bohemoslov; 1985; 34 Suppl():45-8. PubMed ID: 3014581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central action of ergometrine.
    Antkiewicz-Michaluk L
    Pol J Pharmacol Pharm; 1976; 28(6):563-70. PubMed ID: 1034920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central action of adrenaline.
    Jagiełło-Wójtowicz E
    Acta Physiol Pol; 1981; 32(2):169-80. PubMed ID: 7196677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological studies on the venomous spotted butterfish (Scatophagus argus Linn) sting extract on experimental animals.
    Muhuri D; Karmakar S; Dasgupta SC; Nagchaudhuri AK; Gomes A
    Indian J Exp Biol; 2004 May; 42(5):461-7. PubMed ID: 15233469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central action of glaucine in rodents.
    Jagiełło-Wójtowicz E; Kleinrok Z; Jusiak L; Matuszek B; Daniłoś J; Chodakowska A
    Acta Pol Pharm; 1994; 51(2):179-84. PubMed ID: 7863789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonequilibrium alpha adrenergic blockade and neuroleptic activity of N-ethoxycarbonyl-1,dihydroquinoline (BC-347).
    Martel RR
    J Pharmacol Exp Ther; 1969 Mar; 166(1):44-51. PubMed ID: 4304784
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacological actions of tentacle extract of the jellyfish, Acromitus rabanchatu, occurring in the Bay of Bengal.
    Ghosh TK; Gomes A; Chaudhuri AK
    Indian J Exp Biol; 1990 Jan; 28(1):39-42. PubMed ID: 1973149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.